Shots:
- The AURORA 2 involves assessing Lupkynis vs control arm in 216 patients who have completed P-III AURORA 1 study for 1 year
- Results: reduction in UPCR from pre-treatment baseline to year 2 (-3.1 vs -2.1 mg/mg); reduction proteinuria b/w 1 & 2year (1.0 vs 0.6 mg/mg); stable renal function. In general, the interim analysis of AURORA 2 showed that the patients treated with Lupkynis for up to 2yrs. sustained reductions in proteinuria, with no change in mean eGFR @104wks.
- Additionally, the EULAR presentation will highlight RWE suggesting reduced economic burden to healthcare payers when achieving lower LN disease activity
Click here to read full press release/ article | Ref: Businesswire | Image: Businesswire
The post Aurinia to Present Results of Lupkynis (voclosporin) in AURORA 2 Continuation Study for Lupus Nephritis at EULAR 2021 first appeared on PharmaShots.
